Meta-analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC): an Update on 4,798 Patients.

Pierre Blanchard,Anne W. M. Lee,Julie Leclercq,Sophie Marguet,Wai Tong Ng,Jun Ma,Anthony T. C. Chan,Peiyu Huang,Guopei Zhu,Daniel T. T. Chua,Hai Qiang Mai,Joseph Wee,Dora L. W. Kwong,James Moon,Kwan Hwa Chi,George Fountzilas,Masuto Hareyama,Li Zhang,Jean Bourhis,Jean-Pierre Pignon

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.6022

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:6022 Background: In a previous MAC-NPC individual patient data (IPD) meta-analysis, the addition of chemotherapy (CT) to radiotherapy improved overall survival (OS) in nasopharyngeal carcinoma (NPC; Baujat IJROBP 2006). There was an interaction between the timing of CT and treatment effect, with an OS benefit restricted to the concomitant (+/- adjuvant) timing. Since other trials have been conducted, this meta-analysis was updated. Methods: Trials of radiotherapy (RT) with or without CT in patients with non-metastatic NPC were identified and updated IPD obtained. Both Western and Chinese medical literatures were searched. OS was the main endpoint. The fixed-effect model was used. All analyses were pre-specified. Results: Overall 19 trials and 4,798 pts were included. One 2x2 trial was counted twice and 5,020 pts were analyzed. Patients characteristics were well balanced (60% < 50 years, 75% male, 60% PS 0, 90% stage III-IV and 96% WHO grade 2-3). Median follow-up was 7.1 years. There was a significant benefit in favor of CT regarding OS (hazard ratio (HR) [95% confidence interval]: 0.79 [0.72;0.86], p <0.0001; absolute benefit at 5 years=6.4%). There was a significant interaction between treatment effect on OS and the timing of CT (p=0.01) in favor of concomitant CT (without adjuvant CT: HR 0.79 [0.68;0.92]; with adjuvant CT: HR 0.65 [0.56;0.76]) compared to induction CT (HR 0.96 [0.80;1.16]) or adjuvant CT (HR 0.93 [0.70;1.24]), which explained the statistical heterogeneity. Restriction of the analysis to trials with a control arm with RT alone led to similar results. The benefit of the addition of CT was consistent for all endpoints: progression-free survival (HR 0.76 [0.70;0.82], p<0.0001), loco-regional control (HR 0.74 [0.65;0.85], p<0.0001), distant control (0.68 [0.60;0.76], p<0.0001) and NPC related mortality (0.73 [0.66;0.81], p<0.0001). There was no significant interaction between treatment effect on OS and patient covariate (age, sex, tumor stage). Conclusions: The addition of concomitant chemotherapy, with or without adjuvant CT, significantly improves survival in patients with locally advanced nasopharyngeal carcinoma. Supported by PHRC and LNCC